Outcome of Emicizumab Prophylaxis in Patients of Haemophilia A with or without Inhibitor An interventional study

Outcome of Emicizumab Prophylaxis in Patients of Haemophilia A with or without Inhibitor An Early Experience from A Tertiary Care Hospital From Eastern India - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/071826

Enrollment

Registered

2024-08-02

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D66- Hereditary factor VIII deficiency

Interventions

Intervention1: Emicizumab prophylaxis: Single arm study. Emicizumab prophylaxis with weekly once loading dose of 3mg/kg, subcutaneously, for 4 weeks followed by monthly maintenance dose of 6mg/kg subc

Eligibility

Inclusion criteria

Inclusion criteria: All patients having severe Haemophilia A and moderate Haemophilia A with bleeding phenotype with or without inhibitor are included in the study

Exclusion criteria

Exclusion criteria: Haemophilia B patients and patients of other coagulation disorders are excluded from the study

Design outcomes

Primary

Measure	Time frame
Number of bleeding episodesTimepoint: at 1 year, 2 year, 3 year, 4 year, 5 year	—

Secondary

Measure	Time frame
To assess joint healthTimepoint: at 1 year, 2 year, 3 year, 4 year, 5 year	—

Countries

India

Contacts

Public ContactBijita Dutta

ESIPGIMSR, ESIC Medical College and Hospital, Joka, Kolkata

bijitadutta123@gmail.com09433751725

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026